Nicorette QuickMist Dosage/Direction for Use

Posology: Behavioural therapy advice and support will normally improve the success rate.
Adults and Elderly: Up to 3 sprays per hour may be used. Do not exceed 2 sprays per dosing episode and do not exceed 48 sprays (3 sprays per hour, over 16 hours) in any 24-hour period.
Abrupt Smoking Cessation: For smokers willing and ready to stop smoking immediately.
Subjects should stop smoking completely during the course of treatment with Nicorette QuickMist.
The following lists the recommended usage schedule for the oromucosal spray during full treatment (Step I) and during tapering (Step II and Step III).
Step I: Weeks 1-6: Use 1 or 2 sprays when cigarettes normally would have been smoked or if cravings emerge. If after a single spray, cravings are not controlled within a few minutes, a second spray should be used. If 2 sprays are required, future doses may be delivered as 2 consecutive sprays.
Most smokers will require 1-2 sprays every 30 minutes to 1 hour.
Step II: Weeks 7-9: Start reducing the number of sprays per day. By the end of week 9, subjects should be using HALF the average number of sprays per day that was used in Step I.
Step III: Weeks 10-12: Continue reducing the number of sprays per day so that subjects are not using more than 3 sprays per day during week 12. Then stop using Nicorette Quickmist.
Example: If an average of 15 cigarettes per day are usually smoked, 1-2 sprays should be used at least 15 times during the day.
To help stay smoke free after Step III, subjects may continue to use the oromucosal spray in situations when they are strongly tempted to smoke. One spray may be used in situations where there is an urge to smoke, with a second spray if one spray does not help within a few minutes. No more than three sprays per day should be used during this period.
Gradual cessation through progressive reduction in smoking: For smokers who are not willing or ready to quit abruptly.
The oromucosal spray is used between periods of smoking in order to prolong the smoke-free intervals and with the intention to reduce smoking as much as possible. The patient should be aware that an incorrect use of the spray may enhance adverse effects.
A cigarette is replaced with one dose (1-2 sprays) and a quit attempt should be made as soon as the smoker feels ready and no later than 12 weeks after start of treatment. If a reduction in cigarette consumption has not been achieved after 6 weeks of treatment, a healthcare professional should be consulted. After quitting smoking, gradually reduce the number of sprays per day. When subjects have reduced to 2-4 sprays per day, oromucosal spray should be discontinued.
Regular use of the oromucosal spray beyond 6 months is not recommended. Some ex-smokers may need treatment with the oromucosal spray longer to avoid returning to smoking. Any remaining oromucosal spray should be retained to be used in the event of sudden cravings.
Administration of nicotine should be stopped temporarily if any symptoms of nicotine excess occur. Nicotine intake should be decreased by either lowering dosing frequency or strength if nicotine excess symptoms persist.
Paedriatric population: Do not administer Nicorette QuickMist to persons under 18 years of age without recommendation from a healthcare professional. There is no experience of treating adolescents under the age of 18 with Nicorette QuickMist.
Method of administration: After priming, point the spray nozzle as close to the open mouth as possible. Press firmly the top of the dispenser and release one spray into the mouth, avoiding the lips. Subjects should not inhale while spraying to avoid getting spray into the respiratory tract. For best results, do not swallow for a few seconds after spraying.
Subjects should not eat or drink when administering the oromucosal spray.